Authors: Jerkeman, M Kaasa, S Hjermstad, M Kvaloy, S Cavallin-Stahl, E

Citation: M. Jerkeman et al., Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma - A Nordic lymphoma group trial, MED ONCOL, 18(1), 2001, pp. 85-94

Authors: Messori, A Vaiani, M Trippoli, S Rigacci, L Jerkeman, M Longo, G

Citation: A. Messori et al., Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP, BR J CANC, 84(3), 2001, pp. 303-307

Authors: Rodriguez-Catarino, M Jerkeman, M Ahlstrom, H Glimelius, B Hagberg, H

Citation: M. Rodriguez-catarino et al., Residual mass in aggressive lymphoma - Does size, measured by computed tomography, influence clinical outcome?, ACTA ONCOL, 39(4), 2000, pp. 485-489

Authors: Jerkeman, M Anderson, H Cavallin-Stahl, E Dictor, M Hagberg, H Johnson, A Kaasa, S Kvaloy, S Sundstrom, C Akerman, M

Citation: M. Jerkeman et al., CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial, ANN ONCOL, 10(9), 1999, pp. 1079-1086

Authors: Jerkeman, M Johansson, B Akerman, M Cavallin-Stahl, E Kristoffersson, U Mitelman, F

Citation: M. Jerkeman et al., Prognostic implications of cytogenetic aberrations in diffuse large B-celllymphomas, EUR J HAEMA, 62(3), 1999, pp. 184-190